Bleomycin Adverse Effects: What the Label and Studies Report

How bleomycin is used and who administers it

Bleomycin is a prescription cytotoxic antibiotic agent. It is administered by specialist clinical teams in hospitals, infusion units, operating rooms and critical care settings, under the supervision of a physician experienced in cancer chemotherapy, as product labeling states. It is not a medicine that a person prepares or administers independently, and this page contains no dosing, reconstitution or administration information.

Approved labeling describes bleomycin for the palliative management of squamous cell carcinoma, Hodgkin lymphoma, non-Hodgkin lymphoma and testicular carcinoma, and for use as a sclerosing agent in malignant pleural effusion. Any application outside those labeled indications is investigational, including the intralesional dermatologic and intrapericardial uses described in the literature summarised below. Decisions about whether bleomycin belongs in a regimen, and about any symptom that appears during or after treatment, sit with the prescribing specialist; talk to your prescriber.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any symptom, medicine or treatment decision.

The boxed warning in product labeling

United States labeling for bleomycin for injection carries a boxed warning. The boxed warning describes pulmonary fibrosis as the most severe toxicity associated with the drug, notes that it occurs more frequently in older patients and in patients receiving higher cumulative amounts, and states that pulmonary toxicity can occur at lower exposures as well. The boxed warning also describes an idiosyncratic reaction reported in patients with lymphoma, consisting of hypotension, mental confusion, fever, chills and wheezing. Labeling directs that the drug be given under the supervision of a qualified physician and that pulmonary status be monitored.

Because that warning sets the frame for everything else, the sections that follow begin with the lungs, then move to the serious reactions and precautions labeling lists, then to the reactions labeling groups as common.

Pulmonary adverse events: What Studies Report

A 2001 review in Chest examined bleomycin-induced pneumonitis and described it as the principal dose-limiting toxicity of the drug, discussing clinical presentation, risk factors and diagnostic difficulty in oncology patients (PMID 11502668). That review is a narrative synthesis rather than a controlled trial, so it describes patterns clinicians observed rather than event rates from a randomised population.

Imaging findings have also been reported. A 2021 report in the Journal of the Pakistan Medical Association described bleomycin toxicity as it appeared on FDG PET CT, noting that treatment-related lung changes can be mistaken for disease activity on scans performed during or after chemotherapy (PMID 34580536). Researchers in that report framed the imaging appearance as a diagnostic pitfall rather than a measure of how often toxicity occurs.

Management of established pulmonary toxicity has been explored in small reports. A 2020 paper in the Turkish Thoracic Journal described imatinib treatment for bleomycin-induced pulmonary toxicity, presenting it as an option investigated when conventional management did not control the process (PMID 33352104). That work is investigational and does not represent an approved treatment pathway.

Perioperative exposure has been raised as a separate concern. A 2023 case report in Sarcoidosis, Vasculitis, and Diffuse Lung Diseases discussed bleomycin and perioperative care, describing the attention given to patients with prior bleomycin exposure when anaesthesia and supplemental oxygen are planned (PMID 37712370). A single case report describes one patient course and cannot establish frequency.

The biology behind the lung injury has been reviewed in detail. A 2024 review in Cell Biochemistry and Biophysics summarised mechanisms of bleomycin-induced lung fibrosis and catalogued therapeutic targets and approaches under investigation (PMID 38955925). Much of that mechanistic literature comes from animal work, because bleomycin is widely used to model fibrosis experimentally rather than because the models were designed to quantify human risk.

Why bleomycin-free regimens have been studied

Pulmonary toxicity has influenced regimen design in lymphoma. A 2019 evaluation in Expert Review of Hematology assessed brentuximab vedotin as a treatment option for stage III and IV Hodgkin lymphoma, a setting in which bleomycin-containing combination chemotherapy had long been standard (PMID 31432732). That review reported on an alternative approach rather than on bleomycin toxicity rates directly.

Skin and mucous membrane reactions: What Studies Report

Labeling lists cutaneous and mucosal toxicity among the most frequently reported reactions, including erythema, rash, striae, vesiculation, hyperpigmentation, skin tenderness, hyperkeratosis, nail changes, alopecia, pruritus and stomatitis.

A distinctive pattern has been documented in case literature. A 2022 case report in BMJ Case Reports described flagellate dermatitis occurring during bleomycin chemotherapy and examined the question of causality in that patient (PMID 35863861). The report describes a single case, so it documents an association in one patient rather than a rate across a treated population.

Systemic, constitutional and other reactions the label lists

Beyond the boxed warning, labeling describes fever and chills, which it notes are common and typically occur within hours of administration; nausea, vomiting, anorexia and weight loss; local pain at injection sites and phlebitis; and vascular toxicities reported in patients receiving bleomycin in combination regimens, including Raynaud phenomenon. Labeling also describes hypersensitivity and anaphylactoid reactions, renal and hepatic toxicity as rare events, and the need for dose consideration in renal impairment. Those statements come from product labeling rather than from the studies cited on this page.

Body system summary table

Investigational routes described in the literature: What Studies Report

Several published reports describe routes and indications that are investigational rather than labeled. A 2020 clinical study in the Journal of Cosmetic Dermatology evaluated intralesional injection of bleomycin in the treatment of xanthelasma palpebrarum (PMID 31930760). A 2022 report in Acta Clinica Belgica examined intrapericardial bleomycin instillation in malignant cardiac tamponade and reported on safety and efficacy outcomes in that setting (PMID 32623970). These reports describe specialist procedures performed in clinical environments and are summarised here only to show what the literature covers.

Preclinical work on toxicity and delivery: What Studies Report

Because bleomycin reliably produces lung injury in animals, it serves as the standard laboratory model of fibrosis, and much preclinical work uses it to test candidate antifibrotic agents. A 2022 study in ACS Pharmacology and Translational Science evaluated a specific dual ROCK inhibitor against bleomycin-induced pulmonary fibrosis in rats (PMID 36110377). Findings in rodents do not transfer directly to people.

Other preclinical work has examined the molecule itself. A 2020 paper in Bioorganic and Medicinal Chemistry Letters reported HSP70 induction by bleomycin metal core analogs (PMID 32044184), and a 2023 study in Molecules described the antitumor effect of a bleomycin nanoaerosol in a murine carcinoma model (PMID 37241899). Both are laboratory investigations rather than human safety studies, and neither establishes an adverse event profile in patients.

How to read this evidence

The literature summarised above mixes narrative reviews, single case reports, imaging series, small clinical studies and animal experiments (PMID 11502668, PMID 35863861, PMID 38955925). Case reports document that an event occurred in one person; they do not establish how often it occurs. Reviews organise existing observations and inherit the limits of the studies they summarise. Animal studies describe what happened in that species under laboratory conditions. Frequency estimates for labeled reactions come from product labeling and from the clinical trials that supported approval, not from the individual reports cited here.

Questions that belong with the specialist team

Monitoring plans, cumulative exposure tracking, pulmonary function testing, imaging interpretation, management of fever or skin changes during treatment, and planning around surgery and oxygen are all handled by the treating oncology, pulmonary and anaesthesia teams. New or worsening cough, breathlessness, chest discomfort, rash, fever or any other symptom during or after treatment is information for the prescribing clinician; talk to your prescriber rather than drawing conclusions from published summaries.

References

• Bleomycin-induced pneumonitis (Chest, 2001)
• Imatinib Treatment for Bleomycin-Induced Pulmonary Toxicity (Turkish Thoracic Journal, 2020)
• Mechanisms of Bleomycin-induced Lung Fibrosis: A Review of Therapeutic Targets and Approaches (Cell Biochemistry and Biophysics, 2024)
• An evaluation of brentuximab vedotin as a treatment option for stage III/IV Hodgkin lymphoma (Expert Review of Hematology, 2019)
• Evaluating a Specific Dual ROCK Inhibitor against Bleomycin-Induced Idiopathic Pulmonary Fibrosis in Rats (ACS Pharmacology and Translational Science, 2022)
• Intralesional injection of bleomycin in the treatment of xanthelasma palpebrarum: A clinical study (Journal of Cosmetic Dermatology, 2020)
• Bleomycin Toxicity - Findings on FDG PET CT (JPMA. The Journal of the Pakistan Medical Association, 2021)
• Flagellate dermatitis in bleomycin chemotherapy: a causality? (BMJ Case Reports, 2022)
• Malignant cardiac tamponade: safety and efficacy of intrapericardial bleomycin instillation (Acta Clinica Belgica, 2022)
• HSP70 induction by bleomycin metal core analogs (Bioorganic and Medicinal Chemistry Letters, 2020)
• Antitumor Effect of Bleomycin Nanoaerosol in Murine Carcinoma Model (Molecules, 2023)
• Bleomycin and perioperative care: a case report (Sarcoidosis, Vasculitis, and Diffuse Lung Diseases, 2023)